Gosset Year Founded
2006
Ownership
Private
Employees
~10
Therapeutic Areas
Stage
Phase 1
Modalities
Aeromics General Information
Developing AER-271, an intravenous aquaporin-4 inhibitor, currently in Phase 1 safety trial. Planning Phase 2 efficacy trial for prevention of cerebral edema in severe acute ischemic stroke.
Contact Information
Drug Pipeline
AER-271
Phase 1Key Partnerships
Aeromics Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Later Stage VC | Oct 19, 2017 | $9.4M | Completed | Phase 1 |
To view Aeromics's complete valuation and funding history, request access »
Aeromics Investors
Total raised: $14.07M, with last funding of $9.41M approximately 7 years ago (Series A)
Investor Type: Venture Capital
Holding: Minority